We are investigating the safety and effectiveness of BGB-16673 combined with other treatments for patients with relapsed or refractory B-cell malignancies. This study aims to find the best dose and assess how well the treatment works.
Health conditions and diseases that the clinical trial is designed to study and treat.
Relapsed or Refractory B-Cell Malignancies refer to types of blood cancers, including various lymphomas and leukemias, that have either returned after treatment or have not responded to initial therapies. These conditions can be challenging to treat and often require specialized care.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
